Form 4: Equillium CSO Granted 1.025M Stock Options

Equillium's Chief Scientific Officer and Director, Stephen Connelly, was granted 1,025,000 employee stock options with an exercise price of $1.74.

Summary

• Stephen Connelly, Chief Scientific Officer and Director of Equillium, Inc., was granted 1,025,000 employee stock options.
• The transaction date for this grant is August 29, 2025.
• The exercise price for these options is $1.74 per share.
• The options have an expiration date of August 28, 2035.
• The vesting schedule for the options is 25% on the first anniversary of the vesting commencement date, with the remaining 75% vesting in 36 equal monthly installments over the subsequent three years.
• This transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: The sentiment is mildly positive. While a routine compensation event, it signifies continued executive commitment and alignment with shareholder interests. There are no immediate negative financial implications, though future dilution is a consideration.

Positives

• The grant of stock options aligns the interests of the Chief Scientific Officer with those of shareholders, providing an incentive for long-term company performance.
• The transaction was pre-planned under a Rule 10b5-1(c) plan, indicating a structured approach to executive compensation.

Negatives

• The exercise of these options in the future could lead to dilution for existing shareholders, although this is a standard aspect of equity compensation plans.

Future Outlook

The filing details a future grant of stock options with a specific vesting schedule, indicating a long-term incentive structure for the Chief Scientific Officer. The vesting schedule implies future share acquisitions over several years.

Industry Context

The grant of stock options to a key executive like the Chief Scientific Officer is a common practice in the biotechnology and pharmaceutical industries. It serves as a critical component of executive compensation packages, designed to attract, retain, and motivate talent by aligning their financial interests with the long-term success of the company.

Comparison to Industry Standards

• The structure of this option grant, including the vesting schedule and the use of a Rule 10b5-1 plan, is consistent with standard executive compensation practices observed across the biotechnology sector for companies of similar size and development stage as Equillium, Inc.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from increased executive alignment and motivation.
• Stephen Connelly (Reporting Person): Receives a significant long-term incentive tied to the company's stock performance.

Next Steps

• The options will begin vesting on the first anniversary of the vesting commencement date, with subsequent monthly vesting over the following three years.
• Stephen Connelly may exercise these options to acquire common stock upon vesting, subject to the expiration date.

Key Dates

Keywords

Equillium, EQ, Stock Options, Insider Transaction, Form 4, Stephen Connelly, Chief Scientific Officer, Executive Compensation, Rule 10b5-1